91 DOCUMENTO SIPREC 2022 mic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013. 36(12):4022-9. 17. Nissen SE, Wolski KE, Prcela L et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors. JAMA. 2016 . 315(10):990-1004. 18. Wilding J, Batterham RL, CalannaS, Davies M et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. 384(11):989 19. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. 397(10278):971-984. 20. Wadden TA, Bailey TS, Billings LK, Davies M, et al. STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. 325(14):14031413. 21. Rubino D, Abrahamsson N, Davies M, Hesse D, et al. STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.;325(14):1414-1425. 22. Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, N Engl J Med. 2016. 375(19):1834-1844. 23. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. 397:173648.. 24. Rosenstock J, Wysham C, Frías JP et al Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021. 398(10295):143-155.
RkJQdWJsaXNoZXIy NDUyNTU=